These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 24046259)
1. Time trends in glioblastoma multiforme survival: the role of temozolomide. Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
3. Glioblastoma management in the temozolomide era: have we improved outcome? Lwin Z; MacFadden D; Al-Zahrani A; Atenafu E; Miller BA; Sahgal A; Menard C; Laperriere N; Mason WP J Neurooncol; 2013 Nov; 115(2):303-10. PubMed ID: 23979682 [TBL] [Abstract][Full Text] [Related]
4. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855 [TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
7. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Darefsky AS; King JT; Dubrow R Cancer; 2012 Apr; 118(8):2163-72. PubMed ID: 21882183 [TBL] [Abstract][Full Text] [Related]
8. Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Niyazi M; Schwarz SB; Suchorska B; Belka C Strahlenther Onkol; 2012 Feb; 188(2):154-9. PubMed ID: 22231634 [TBL] [Abstract][Full Text] [Related]
9. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. Michaelsen SR; Christensen IJ; Grunnet K; Stockhausen MT; Broholm H; Kosteljanetz M; Poulsen HS BMC Cancer; 2013 Sep; 13():402. PubMed ID: 24004722 [TBL] [Abstract][Full Text] [Related]
10. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
11. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Rønning PA; Helseth E; Meling TR; Johannesen TB Neuro Oncol; 2012 Sep; 14(9):1178-84. PubMed ID: 22869622 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878 [TBL] [Abstract][Full Text] [Related]
13. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394 [TBL] [Abstract][Full Text] [Related]
15. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710 [TBL] [Abstract][Full Text] [Related]
16. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Rock K; McArdle O; Forde P; Dunne M; Fitzpatrick D; O'Neill B; Faul C Br J Radiol; 2012 Sep; 85(1017):e729-33. PubMed ID: 22215883 [TBL] [Abstract][Full Text] [Related]
17. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. Ashby LS; Smith KA; Stea B World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526 [TBL] [Abstract][Full Text] [Related]
18. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723 [TBL] [Abstract][Full Text] [Related]
19. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Yabroff KR; Harlan L; Zeruto C; Abrams J; Mann B Neuro Oncol; 2012 Mar; 14(3):351-9. PubMed ID: 22241797 [TBL] [Abstract][Full Text] [Related]
20. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Graus F; Bruna J; Pardo J; Escudero D; Vilas D; Barceló I; Brell M; Pascual C; Crespo JA; Erro E; García-Romero JC; Estela J; Martino J; García-Castaño A; Mata E; Lema M; Gelabert M; Fuentes R; Pérez P; Manzano A; Aguas J; Belenguer A; Simón A; Henríquez I; Murcia M; Vivanco R; Rojas-Marcos I; Muñoz-Carmona D; Navas I; de Andrés P; Mas G; Gil M; Verger E Neuro Oncol; 2013 Jun; 15(6):797-805. PubMed ID: 23460319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]